These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 9411387)

  • 1. Respiratory syncytial virus PREVENT Study questions.
    Dransfield D; Kessler D; McCarthy C
    Pediatrics; 1997 Dec; 100(6):1044-5. PubMed ID: 9411387
    [No Abstract]   [Full Text] [Related]  

  • 2. Respiratory syncytial virus PREVENT Study questions.
    Moler FW
    Pediatrics; 1997 Dec; 100(6):1043-4; author reply 1045. PubMed ID: 9411385
    [No Abstract]   [Full Text] [Related]  

  • 3. Respiratory syncytial virus PREVENT Study questions.
    Raju TN
    Pediatrics; 1997 Dec; 100(6):1044; author reply 1045. PubMed ID: 9411386
    [No Abstract]   [Full Text] [Related]  

  • 4. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoprophylaxis of respiratory syncytial virus infection.
    Simoes EA
    Indian Pediatr; 2000 Mar; 37(3):243-7. PubMed ID: 10750065
    [No Abstract]   [Full Text] [Related]  

  • 7. Prophylaxis against respiratory syncytial virus in high-risk infants: administration of immune globulin and epidemiological surveillance of infection.
    Handal G; Logvinoff MM; Zegarra N; Allen L; Jesurun A; Levin G; Thida A
    Tex Med; 2000 May; 96(5):58-61. PubMed ID: 10843015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost estimates of prophylaxis.
    Moler F
    Arch Pediatr Adolesc Med; 2001 Feb; 155(2):199-200. PubMed ID: 11177100
    [No Abstract]   [Full Text] [Related]  

  • 9. Questions about palivizumab (Synagis).
    Lee SL; Robinson JL
    Pediatrics; 1999 Feb; 103(2):535; author reply 535-6. PubMed ID: 10026069
    [No Abstract]   [Full Text] [Related]  

  • 10. Prophylaxis for severe respiratory syncytial virus disease.
    Kupecz D
    Nurse Pract; 1996 Sep; 21(9):116-8. PubMed ID: 8884798
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prophylaxis of respiratory syncytial virus infections with palivizumab].
    Danés Carreras I; Arnau De Bolós JM
    An Esp Pediatr; 2002 Apr; 56(4):289-91. PubMed ID: 11927094
    [No Abstract]   [Full Text] [Related]  

  • 12. Respiratory syncytial virus prophylaxis in a high-risk population in Argentina: a cost-effectiveness analysis.
    Rodríguez SP; Fariña D; Bauer G
    Pediatr Infect Dis J; 2008 Jul; 27(7):660-1. PubMed ID: 18520447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RSV-IGIV therapy: a cost/benefit analysis.
    Thakur BK; Wu LR; Schaeufele JF
    Pediatrics; 1997 Sep; 100(3 Pt 1):417-8. PubMed ID: 9304108
    [No Abstract]   [Full Text] [Related]  

  • 14. RSV-IG (respigam).
    Snyder R
    Neonatal Netw; 1998 Apr; 17(3):63-5. PubMed ID: 9601353
    [No Abstract]   [Full Text] [Related]  

  • 15. Annual variation in respiratory syncytial virus season and decisions regarding immunoprophylaxis with palivizumab.
    Meissner HC; Anderson LJ; Pickering LK
    Pediatrics; 2004 Oct; 114(4):1082-4. PubMed ID: 15466107
    [No Abstract]   [Full Text] [Related]  

  • 16. Respiratory syncytial virus immune globulin and conflict of interest.
    Groothuis JR
    N Engl J Med; 1998 Nov; 339(22):1644. PubMed ID: 9867534
    [No Abstract]   [Full Text] [Related]  

  • 17. RespiGam/PREVENT study questioned.
    Bouthillier MJ
    Pediatrics; 1997 Aug; 100(2 Pt 1):275-6. PubMed ID: 9254383
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Reeve CA; Whitehall JS; Buettner PG; Norton R; Reeve DM; Francis F
    J Paediatr Child Health; 2006 May; 42(5):253-8. PubMed ID: 16712554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Respiratory syncytial virus infections and preventive options].
    Moll HA; de Groot R
    Ned Tijdschr Geneeskd; 2000 Apr; 144(15):724-5. PubMed ID: 10778722
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention of respiratory syncytial virus infection in high risk infants.
    Prince AM; Jacobs RF
    J Ark Med Soc; 2001 Oct; 98(4):115-8. PubMed ID: 11594047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.